Navigation Links
Inspiration Biopharmaceuticals Expands Leadership Team with Four New Hires
Date:12/22/2011

College of Pharmacy and Allied Health Sciences.

John P. Butler, Chief Executive Officer of Inspiration, commented, "Howard, Dan, Nikki and Karen join Inspiration at a very exciting time in the Company.  As Inspiration advances its lead programs, IB1001 and OBI-1, towards commercialization, we are focused on building a world-class company dedicated to improving the life of individuals with hemophilia.  The new additions bring invaluable and diverse experiences to the Company and will undoubtedly build upon the established strengths and expertise of the leadership team.  We expect our new Boston-area location will continue to attract great talent."

Dr. Levy, Mr. Regan, Ms. Hadas and Ms. Tubridy join Inspiration's executive leadership team which includes John Butler, Mike Griffith, Ph.D. (President and Chief Scientific Officer), Andrew Grethlein, Ph.D. (Executive Vice President and Chief Operating Officer) and Gordon H. Busenbark (Senior Vice President and Chief Financial Officer).  Inspiration's team has broad expertise and experience in hemophilia product development, biologics manufacturing and the successful commercialization of products to treat hemophilia as well as chronic orphan diseases.

About Inspiration BiopharmaceuticalsInspiration Biopharmaceuticals is dedicated exclusively to developing treatments for hemophilia, with a primary mission to broaden access to care to safe and effective recombinant therapies and advance innovation for people living with these conditions.  Inspiration has a broad portfolio of recombinant hemophilia products, which includes two products in late-stage clinical development and two preclinical programs.

Inspiration's lead product candidates are IB1001, an intravenous recombinant factor IX (FIX) product for the treatment and prevention of bleeding in individuals with hemophilia B, and OBI-1, an intravenous recombinant porcine factor VIII (FVIII) product for the treatment
'/>"/>

SOURCE Inspiration Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
2. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
3. Inspiration for My Sisters Keeper Speaks Out
4. National Expressions of Courage Art Contest Unveils Stories of Inspiration
5. Inspiration Biopharmaceuticals OBI-1 Receives Orphan Drug Designation in Europe
6. Inspiration Biopharmaceuticals Awarded Two Grants Under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP)
7. Siemens MAMMOMAT Inspiration Digital Mammography Commercially Available in U.S.
8. Inspiration Biopharmaceuticals Treats First Patient in Pivotal Study of OBI-1 for Acquired Hemophilia A
9. Inspiration Biopharmaceuticals Demonstrates Non-Inferiority of IB1001, Its Recombinant Factor IX for Hemophilia B
10. Inspiration Biopharmaceuticals Announces Data from OBI-1 Pivotal-Stage Program in Hemophilia at 23rd ISTH Congress
11. Heskas 2011 "Inspiration in Action" Contest Begins: Support the Veterinary Profession and Help Animals in Need
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Pomerantz LLP has filed a class action ... EDAP ) and certain of its officers.  ... Southern District of New York , ... class consisting of all persons or entities who purchased ... 2014, inclusive (the "Class Period"). This class action seeks to ...
(Date:8/29/2014)... Thoratec Corporation (NASDAQ: THOR ), ... to save, support and restore failing hearts, said today ... Global Healthcare Conference on Wednesday, September 10. ... Officer, will provide an update on the company, beginning ... Daylight Time).   A webcast of the ...
(Date:8/29/2014)... 2014 Research and Markets  has announced the ... 2014" report to their offering. The ... of the largest segments of pharmaceuticals industry. The numbers of ... available therapies were unable to meet the market requirements. There ... CNS disorder, especially over the past two decades. The market ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 3US CNS Disorders Drug Pipeline Insight 2014 2
... Tenn. , Jan. 20 Cumberland Pharmaceuticals Inc. ( ... ) Injection, an intravenous form of ibuprofen, to Haitian relief effort. ... for the treatment of pain and reduction of fever in ... continue to deteriorate, Caldolor is expected to help those suffering from ...
... , , LOS ANGELES , ... that it has joined forces with New Jersey -based ... create the nation,s first IVF insurance program. The Assisted Reproduction ... financial solutions for the ever-rising costs of In Vitro Fertilization ...
Cached Medicine Technology:Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort 2Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort 3New Life Agency, Inc. Joins Forces With The Diamond Institute and Walgreens Specialty Pharmacy to Introduce the Nation's First In Vitro Fertilization Insurance Program 2New Life Agency, Inc. Joins Forces With The Diamond Institute and Walgreens Specialty Pharmacy to Introduce the Nation's First In Vitro Fertilization Insurance Program 3
(Date:8/29/2014)... 2014 Healthpointe is proud to welcome ... Rodas will be practicing out of Healthpointe’s newest office ... of Healthpointe’s orthopedic team, Dr. Rodas is ... board-certified in occupational medicine. , Among Dr. Rodas’ ... Director of Raytheon, the world-class defense and aerospace company. ...
(Date:8/29/2014)... Healthpointe is pleased to provide ... students via Clinical Rotations. Physical Therapy ... Healthpointe providers and specialists throughout their daily clinical ... experience and learn professional preparation. , ... into several patient care techniques and expand their ...
(Date:8/29/2014)... August 29, 2014 Pursuing its deepest ... set to unveil a stunning new design that promises ... figures, the highly notable surrogacy platform has witnessed a ... over 13,000 visitors a month, the FindSurrogateMother.com community is ... toward one common goal — the precious gift of ...
(Date:8/29/2014)... trials based on administering antidepressants for acute and ... trials are needed to determine whether these drugs ... regular basis., Dr. Ian Gilron, a professor and ... of Anesthesiology, and his team of seven researchers ... of antidepressants for pain relief post-surgery would work ...
(Date:8/29/2014)... Grove Village, IL (PRWEB) August 29, 2014 ... innovator in hearing wellness solutions, is on its way ... 15-17 at the San Diego Convention Center to exhibit ... those who work in high-noise industrial environments. Etymotic’s safety ... the hottest wearable technology devices at the show. ...
Breaking Medicine News(10 mins):Health News:Dr. Anthony G. Rodas Joins Healthpointe Team at LAX Office 2Health News:Healthpointe is Now Offering Clinical Rotations for Chapman University Physical Therapy Students 2Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 2Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 3Health News:Antidepressants show potential for postoperative pain 2Health News:Etymotic’s Safe Listening Earphones and Earplugs Headed For The 2014 NSC Safety Expo 2
... and global IT giant Tata Consultancy Services (TCS) have ... a global drug development center in Mumbai. ... variety of services in clinical research, including clinical data ... ,"GSK has chosen to partner with TCS because of ...
... official figures.// ,Statistics for 2006 show ... which protects against measles, mumps and rubella, as against the national ... is an increase from the previous year, when the figure was ... 1988, but levels of uptake began to decline after 1998 when ...
... decided to crackdown on unethical doctors who accept gifts from ... entrance. ,This move follows the rocketing costs ... such tests. , According to the new law ... up to 5 years in jail, in terms of prosecution ...
... of persons infected with deadly viruses such as HIV and ... understand how. // , An independent inquiry is soon ... by almost 2000 hemophilia patients, via blood transfusions, in what ... of UK’s National Health Services. , The ...
... the “triple negative” type are destructive and lethal, and tend ... novel// study Published in the May 1, 2007 issue of ... occur commonly among women who are African American and Hispanic, ... socioeconomic status (SES). The study also showed that triple negative ...
... found that the most potent cholesterol-lowering drug is ... blood vessels that can lead to atherosclerosis. ... arteries compared to a placebo,” said John R.Crouse, ... at Wake Forest University School of Medicine. “The ...
Cached Medicine News:Health News:Scotland’s Parents Still a Little Wary of MMR Shot 2Health News:Inquiry into Past NHS Treatment Disaster 2Health News:'Triple Negative' Breast Cancers Seem to Affect the Young, Minority 2Health News:Cholesterol-lowering Drug Effective at Halting Early Atherosclerosis 2
Sprint Quattro Secure™ is a Steroid-Eluting, True Bipolar, Active Fixation ICD Lead....
TVL defibrillation leads have a patented coiled-coil design for faster, easier insertion and more precise intracardiac placement. Designed with an integrated bipolar design, the lead enables high-vol...
The TVL-ADX lead is a thin, high-performing defibrillation lead that offers a true bipolar configuration designed for smarter sensing and low defibrillation threshold for greater patient safety margi...
... SPL defibrillator lead features a ... the flexibility and maneuverability of ... the physician who prefers a ... the SPL lead also promotes ...
Medicine Products: